
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is well-positioned for commercial expansion through their BEACON study which showed significant improvements in cognitive and neuropsychiatric symptoms in patients using ZUNVEYL. Additionally, their CONVERGE and RESOLVE studies, as well as their long-term care commercial team and potential licensing partnerships, provide strong potential for long-term market uptake. With positive financial results and an early settlement agreement that eliminates future royalty and milestone payment obligations, Alpha Cognition is set for success in the long term.
Bears say
Alpha Cognition is valued at $580M utilizing a DCF-based valuation methodology with a 12-month price objective of $20 per share. Risks include potential delays in achieving sales traction for ZUNVEYL, slower market uptake due to pricing pressures or competition, setbacks in clinical testing, and possible dilution risk. The company's pipeline initiatives, specifically a sublingual benzgalantamine formulation, may add value to the company's product portfolio and broaden the addressable market for ZUNVEYL, but these forecasts do not currently include any contribution from this asset.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares